Member Sign In

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

This segment reported worldwide revenues of $86.9 million, up 20.4% year over year.

Revenues in the United States increased 25.5% to $71.3 million on a year-over-year basis. International revenues totaled $15.6 million, up 1.5% year over year.

Upper Extremities

Revenues at this segment totaled $111.2 million, up 14.3% from the prior-year quarter’s level.

In the United States, revenues increased 20.8% on a year-over-year basis to $81.7 million. Internationally, the segment reported revenues worth $29.5 million, down 0.4% year over year.

Biologics

Biologics revenues amounted to $27.2 million in the quarter under review, up 16% on a year-over-year basis.

While international revenues at the segment declined 13.7% to $4.5 million, U.S. revenues summed $22.6 million, up 24.6% year over year.

Sports Med & Other

At this segment, net revenues came in at $4.9 million, down 14.3% on a year-over-year basis.

The segment’s U.S. revenues decreased 2.6% to $2.1 million, while international revenues decreased 21.3% to $2.8 million.

Margin Analysis

In the quarter under review, gross profit totaled almost $183.8 million, up 16.8% year over year. Gross margin was 79.9% of net revenues, which expanded 60 bps from the year-ago quarter.

Selling, general and administrative expenses were $153.3 million, up 11.7% year over year.

Research and development expenses amounted to $16.9 million, up 22.1% year over year.

Operating income in the first quarter of 2019 was $5.9 million against operating loss of $0.9 million in the prior-year quarter.

Guidance Reiterated

For 2019, Wright Medical issued revenue guidance in the band of $954-$966 million. The mid-point of $960 million is below the Zacks Consensus Estimate of $961.2 million. This reflects 15-17% net revenue growth on a constant-currency basis, 11-13% increase on a pro-forma constant-currency basis and 10-12% improvement on an organic constant-currency basis.

The company expects 2019 adjusted earnings per share of 17-25 cents. Notably, the mid-point of 21 cents is in line with the Zacks Consensus Estimate.

Conclusion

Wright Medical exited the first quarter on a promising note. The company's adjusted earnings and revenues outpaced Zacks Consensus Estimate. It expects to deliver double-digit, constant-currency net sales growth each year and maintain adjusted gross margin in the high 70% range every year.

Solid performance at the Upper and the Lower Extremities segments buoys optimism. Further, consistent growth in PERFORM Reversed glenoid and robust contributions from the SIMPLICITI shoulder system continue to impress. Wright Medical is likely to gain from the upcoming launch of REVIVE revision shoulder system as well. Furthermore, management is confident about the recent acquisition of BLUEPRINT and also remains highly optimistic about the Cartiva buyout.

Meanwhile, the company’s increasing operating expenses are worrisome. Additionally, the sports business performed disappointingly in the first quarter. Distribution issues in Europe and Asia as well as foreign currency volatility add to woes. Increased costs related to product launch and re-building infrastructure is expected to keep the margins under pressure.

Stryker delivered first-quarter 2019 adjusted earnings per share of $1.88, beating the Zacks Consensus Estimate by 2.2%. Revenues of $3.52 billion were in line with the Zacks Consensus Estimate.

DENTSPLY reported adjusted earnings per share (EPS) of 49 cents in the first quarter of 2019, beating the Zacks Consensus Estimate of 38 cents. Revenues came in at $946.2 million and surpassed the Zacks Consensus Estimate of $917.1 million.

Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.

These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.

Resources

Client Support

Follow Us

Zacks Mobile App

Zacks Research is Reported On:

Yahoo

MSN

Marketwatch

Nasdaq

Forbes

Investors.com

Morningstar

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25.08% per year. These returns cover a period from January 1, 1988 through March 4, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Visit performance for information about the performance numbers displayed above.

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service.